Apogee Therapeutics, Inc. (APGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$135.07-0.01%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APGE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance zumilokibart into Phase 3 clinical trials for moderate-to-severe atopic dermatitis in the second half of 2026, based on positive Phase 2 APEX Part B results and regulatory interactions.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a May 2026 press release. Management plans to initiate Phase 3 trials of zumilokibart in moderate-to-severe atopic dermatitis in the second half of 2026, based on positive Phase 2 APEX Part B results showing 65.9% EASI-75 response at Week 16. The trajectory is delivering with clear progression from Phase 2 to planned Phase 3 initiation.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Plans to begin Phase 3 trials of zumilokibart in second half of 2026 enabling potential commercial launch in 2029.”
“Phase 3 trials in AD expected later this year following positive Phase 2 Part A results.”
Expand clinical development of zumilokibart into asthma and eosinophilic esophagitis (EoE) with planned Phase 2 trials starting in 2H 2026 and 1H 2027 respectively.
Stated in 3 quarters including 2026-Q1 and 2026-Q2 and a May 2026 press release. Management plans Phase 2 trials for EoE in second half of 2026 and asthma in first half of 2027, supporting the pipeline-in-a-product strategy. The company has reported positive Phase 1b asthma data and is advancing clinical programs accordingly. The trajectory shows active expansion of indications.
“ELEVATE Phase 2a trial in EoE to initiate in 2H 2026; ASPIRE Phase 2b asthma trial to initiate in 1H 2027.”
“Plans to outline broader expansion into asthma and EoE trials later this year.”
Finalize the acquisition by AbbVie, expected to close in third quarter of 2026, subject to customary closing conditions including shareholder and regulatory approvals.
Stated in 2 disclosures including 2026-Q2 and a June 2026 press release. The acquisition by AbbVie is expected to close in Q3 2026, subject to shareholder and regulatory approvals. The transaction values Apogee at approximately $10.9 billion. The trajectory is progressing toward completion with regulatory and shareholder steps pending.
“Pending acquisition by AbbVie expected to close in third quarter of 2026, subject to approvals.”
Secure and utilize strategic financing collaborations, including a $1.3 billion agreement with Blackstone Life Sciences, to support Phase 3 development and commercialization.
Stated in 2 disclosures including 2026-Q2 and a May 2026 material event. The company secured a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion, including an upfront payment of $100 million, to support Phase 3 development and commercialization. The financing supports the capital needs for advancing the pipeline. The trajectory is delivering on financing milestones.
“Strategic financing collaboration with Blackstone Life Sciences announced to provide funding through commercialization.”
Ensure sufficient capital resources to fund operations and development programs through 2029, supporting planned BLA filing and commercialization.
Over the trailing year it converted 0.86x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to Fed net liquidity, the US dollar, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.